Qiagen Stock Price, News & Analysis

QIAGEN announced that its QuantiFERON-TB Gold Plus (QFT-Plus) has received approval from China's NMPA for diagnosing active tuberculosis (TB). This approval enhances QFT-Plus's established market position following previous regulatory success in the U.S. The WHO has also recommended QFT-Plus as the modern gold standard for TB detection, promoting its use along with the new QIAreach QFT in epidemiological research. The QFT-Plus test, which has seen over 1.5 million tests in China since 2013, is noted for easier scalability and accuracy, especially for immunocompromised patients.

QIAGEN (NYSE: QGEN) has completed a U.S. government contract to supply QIAcuity digital PCR systems for wastewater surveillance of SARS-CoV-2. Over 35 systems have been shipped to public health labs, with 70% of U.S. states now utilizing this technology. The QIAcuity platform provides rapid results within two hours, enhancing pandemic response capabilities. This initiative supports public health authorities in monitoring infection spread and mutations, offering crucial near-real-time data. QIAGEN aims to continue aiding public health efforts globally as testing shifts towards infectious disease monitoring.

QIAGEN N.V. (NYSE: QGEN) will announce its fourth quarter and full-year results for 2021 on February 8 at approximately 16:05 EST. A conference call will follow on February 9 at 15:00 Frankfurt time, featuring CEO Thierry Bernard and CFO Roland Sackers. Investors can join via this link or by dialing the respective numbers for the U.S., UK, and Germany.

QIAGEN has launched its QIAwave product line, introducing three nucleic acid extraction kits that significantly reduce environmental waste. The new kits use up to 63% less plastic and 42% less cardboard compared to standard products. This initiative marks a significant move towards sustainability, aiming to decrease plastic packaging waste by an additional 9% in 2022 after a 9.6% reduction in 2021. The company also aims for net-zero carbon emissions by 2050, receiving a top “Prime” rating from ISS ESG for its efforts.

QIAGEN N.V. (NYSE: QGEN) has announced significant enhancements to its QIAstat-Dx syndromic testing solution, aiming to improve testing capacities for pathogens. New tests include a Gastrointestinal panel for U.S. regulatory approval, designed to detect 22 pathogens, and CE-IVD registration for a Meningitis/Encephalitis panel analyzing 15 pathogens. The new QIAstat-Dx Rise platform, launching in mid-2022, features enhanced efficiency with a Smart Drawer system capable of processing up to 160 tests per day. These advancements respond to increased demand for rapid testing amid ongoing health challenges.

QIAGEN N.V. (NYSE: QGEN) has announced the expansion of its QIAcuity digital PCR platform, now offering non-invasive prenatal testing (NIPT) through collaboration with Atila BioSystems and introducing protein analysis capabilities via a partnership with Actome GmbH. The enhancements reduce sample processing time to 2.5 hours and increase multiplexing capabilities. QIAcuity is also highlighted for its application in detecting rare cancer mutations and testing wastewater for SARS-CoV-2. These advancements aim to establish QIAcuity as a new standard in PCR technology.

QIAGEN N.V. (NYSE: QGEN) announced significant expansions to its QuantiFERON franchise, enhancing its tuberculosis detection capabilities and introducing new applications for latent disease detection. The QuantiFERON SARS-CoV-2 assay, launched in December 2021, has received CE marking to measure T-cell responses to COVID-19. Additionally, the QuantiFERON-TB Gold Plus assay now includes more patient groups as approved by the FDA. The QIAreach QuantiFERON-TB test aims to improve TB detection in resource-limited settings and is now approved for public health procurement in over 100 countries.

Denovo Biopharma and QIAGEN announced a collaboration to develop a blood-based companion diagnostic test for patients with diffuse large B-cell lymphoma (DLBCL). This test aims to identify individuals expressing the Denovo Genomic Marker 1 (DGM1), who may respond to Denovo's investigational drug DB102. The development involves a real-time PCR assay for the QIAGEN Rotor-Gene Q MDx instrument, with plans to seek premarket approval from the FDA. Denovo's DB102 is currently in a Phase III trial for DLBCL and glioblastoma multiforme and has received several FDA designations.

QIAGEN has partnered with Denovo Biopharma to develop a blood-based companion diagnostic test for Diffuse Large B-Cell Lymphoma (DLBCL) patients likely to respond to Denovo's investigational drug DB102. The collaboration seeks FDA premarket approval (PMA) alongside the new drug application (NDA) for DB102. This agreement bolsters QIAGEN's precision medicine initiatives and its oncology testing portfolio. The test will detect Denovo Genomic Marker 1 (DGM1), enhancing treatment personalization for DLBCL patients.